Translational Research
Volume 152, Issue 2 , Pages 88-94 , August 2008

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

Received 11 March 2008 ,Revised 15 May 2008 ,Accepted 30 May 2008.

References 

  1. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease?. Chest. 2003;123:1684–1692
  2. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971-2000. MMWR Surveill Summ. 2002;51:1–16
  3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255–1259
  4. Wise RA. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Prev Med. 1997;26:418–421
  5. Chatila WM, Wynkoop WA, Vance G, Criner GJ. Smoking patterns in African Americans and whites with advanced COPD. Chest. 2004;125:15–21
  6. Dransfield MT, Davis JJ, Gerald LB, Bailey WC. Ethnic and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med. 2005;100:1110–1116
  7. Vollmer WM, Enright PL, Pedula KL, et al. Ethnicity and gender differences in the effects of smoking on lung function. Chest. 2000;117:764–772
  8. Egede LE, Zheng D. Ethnic/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health. 2003;93:2074–2078
  9. Silverman BG, Gross TP, Babish JD. Home oxygen therapy care beneficiaries, 1991–1992. Chest. 1997;112:380–386
  10. Taylor AL, Ziesche S, Yancy C, et al. African-american heart failure trial investigators Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057
  11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26
  12. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a long-acting inhaled anticholinergic bronchodilator (A randomized trial). Ann Intern Med. 2005;143:317–326
  13. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–926
  14. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309–315
  15. Standardization of spirometry - 1994 update: statement of the American Thoracic Society. Am J Respir Crit Care Med. 1995;152:S77–S120
  16. Morris JF, Koski A, Temple WP, Claremont A, Thomas DR. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest. 1988;93:123–127
  17. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968
  18. Criner GJ, Sharafkhaneh A, Conoscenti CS, Johnson P, Keyser MT, Cassino C. Efficacy of tiotropium powder in African-American patients with chronic obstructive pulmonary disease. J COPD. 2008;5:35–41
  19. Burchard EG, Ziv E, Coyle N, et al. The importance of ethnicity and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–1175
  20. Dransfield MT, Bailey WC. COPD: ethnic disparities in susceptibility, treatment, and outcomes. Clin Chest Med. 2006;27:463–471
  21. Jha AK, Shlipak MG, Hosmer W, Frances CD, Browner WS. Ethnic differences in mortality among men hospitalized in the Veterans Affairs health care system. JAMA. 2001;285:297–303
  22. Gordon HS, Johnson ML, Ashton CM. Process of care in hispanic, black, and white VA beneficiaries. Med Care. 2002;40:824–833
  23. Wilt TJ, Niewoehner DE, MacDonald R, Kane RL. Diagnosis and management of stable chronic obstructive pulmonary disease. Ann Intern Med. 2007;147:639–653
  24. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43:566–572
  25. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients: Implications of the U.S. Food and Drug Administration approval. Ann Intern Med. 2007;146:52–56
  26. Temple R, Stockbridge NL. BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. Ann Intern Med. 2007;146:57–62
  27. Relling MV, Lin JS, Ayers GD, Evans WE. Ethnic and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643–658
  28. Tornatore KM, Reed KA, Venuto RC. Ethnic differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacotherapy. 1993;13:481–486
  29. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther. 1999;291:1196–1203
  30. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43:943–967
  31. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97:10483–10488

 Supported by honoraria, consultancies, and employment from Boehringer Ingelheim Pharmaceuticals and Pfizer, Inc. (to all authors) and from AstraZeneca, Aventis, Sanofi Pasteur, and GlaxoSmithKline (to D.E.N.). Supported also by grants from Boehringer Ingelheim Pharmaceuticals, Aventis, and Sanofi Pasteur (to K.R.) as well as from Boehringer Ingelheim Pharmaceuticals and GlaxoSmithKline (to D.E.N.).

PII: S1931-5244(08)00155-2

doi: 10.1016/j.trsl.2008.05.011

Translational Research
Volume 152, Issue 2 , Pages 88-94 , August 2008

Article Tools

* Image Usage & Resolution